RT Journal Article SR Electronic T1 Ziv-aflibercept: a novel option for the treatment of polypoidal choroidal vasculopathy JF BMJ Case Reports FD BMJ Publishing Group Ltd SP bcr2015212988 DO 10.1136/bcr-2015-212988 VO 2015 A1 Chetan Videkar A1 Aditya Kapoor A1 Jay Chhablani A1 Raja Narayanan YR 2015 UL http://casereports.bmj.com/content/2015/bcr-2015-212988.abstract AB Polypoidal choroidal vasculopathy (PCV) is an exudative maculopathy usually treated using photodynamic therapy (PDT) and antivascular endothelial growth factor agents. However, these cases may sometimes be refractory to both PDT and ranibizumab or bevacizumab, and may have persistent intra-retinal fluid. Recently, studies have reported that aflibercept may be effective in such resistant cases. However, high cost and limited availability has restricted its use to only a few countries. Ziv-aflibercept (Zaltrap), a systemic analogue of aflibercept, has been tried recently and it has been effective in macular oedema. We report a case of PCV resistant to PDT and ranibizumab, which responded well to intravitreal ziv-aflibercept.